Value based pricing for NHS drugs: an opportunity not to be missed? - Wikidata - wikimedia - TriplyDB

Value based pricing for NHS drugs: an opportunity not to be missed?

Value based pricing for NHS drugs: an opportunity not to be missed?

http://www.wikidata.org/entity/Q36420631

about

Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose.Drugs, money and society (Part II).Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.Patient experience and attitudes toward addressing the cost of breast cancer care.Cost-effectiveness and pricing of antibacterial drugs.Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space Early decision-analytic modeling - a case study on vascular closure devices.Should patients be able to pay top-up fees to receive the treatment they want? No.The value of innovation under value-based pricing.Reading a cost-effectiveness or decision analysis study: Five things to consider.Decision analysis for resource allocation in health care.Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors.Value-engineered translation for regenerative medicine: meeting the needs of health systems.The (Ir)relevance of Group Size in Health Care Priority Setting: A Reply to Juth.A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.Operationalizing value-based pricing of medicines : a taxonomy of approaches.Market access of cancer drugs in European countries: improving resource allocation.Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.Sustainable Financing of Innovative Therapies: A Review of Approaches.Economics of ramucirumab for metastatic colorectal cancer.The determinants of cost-effectiveness potential: an historical perspective on lipid-lowering therapies.Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.Impact of patient sample on costs of events in pharmacoeconomic models.Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.PPRS: Not dead yet.Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature.Value-based differential pricing: efficient prices for drugs in a global context.Value of information and pricing new healthcare interventions.Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

P2860

Q21560835-E7BC55E2-B8BB-406C-A604-FC94FFCEBA58 Q30505263-1E2578EA-CA4B-41FF-827B-EE937E0D0DEB Q33596863-A5AE91CB-4622-48B0-90F4-37A94A59F2B8 Q33730376-6C222C46-A347-45E1-9D60-4097001D6742 Q33898127-DF40ED2D-683C-4587-99FC-40BD4F36B86F Q34174858-EEB47CD1-106B-4DE4-ADB3-7FE2D8747DBB Q34174890-B7384C6D-62A8-43E8-AC70-EBBB99F2C5AB Q34196906-EB752D67-46C2-4362-B005-C87C485507D7 Q34457992-4E87A378-4264-4AAE-98A5-127B44A9F508 Q35084162-38293043-F330-4938-8314-9642EFC3366D Q35126801-2E176A89-1682-41FB-A4A5-62D6B945F8EF Q35159488-A35DA1E1-B4CA-459A-B687-F912F7352C69 Q35823418-EB2340A3-04A8-4098-8365-77B097266660 Q36661827-CE1B550D-7E22-4CB2-B961-951F95205098 Q36783257-176CA1E9-5CCA-4E6E-8456-75602C24E90F Q37251702-C2E09F3F-D37C-463D-BF9A-533559C0285B Q37275135-1D0099C8-CCF6-4957-AE0F-B0BF44AB260C Q37293688-D9D4BA12-DFE1-4C8A-BD22-6123E41C58F6 Q37397621-2EEC4E0C-E0F5-43F2-994E-C31A694B3167 Q37422502-81A800CE-2732-46E3-B431-B0A0041D20AD Q37443120-111174D1-9110-4A73-9A73-8F3495F4F953 Q37647963-D77303BF-C761-4DED-B1E2-2688C8012173 Q37875562-6276EB94-F61E-4DCD-B3C2-B46EFB0C1769 Q38016948-5CE00569-C120-487A-80F3-D58EAD470698 Q38074912-3D7EC1BD-CCF1-414D-AF4E-9B5BFDE61593 Q38163486-43BC9495-28C8-4282-8D2B-F8ABE50508AA Q38764032-BD67ABC2-298D-4A44-A962-10291742AB04 Q38842401-44AEBAD6-129A-4144-B0E1-259CBF634AC2 Q38850678-3A2DEC4D-B5C1-421C-B08B-8291F14A2D9E Q39003764-8B14F38A-2B43-45E9-8E65-0B79BD008DE8 Q39437437-0BA8C9CA-2862-4861-8EB4-48F52D115DF1 Q39558757-05A9F7F0-A239-4FAF-94D5-A34C61E3B6A9 Q40041757-74269B2E-175F-46A6-BEB3-2D7CF8823BAA Q41713388-FB659D80-249C-4AE6-AB41-0AD51269401F Q42619132-7A9178F1-7375-4202-AF03-937DF303D9D9 Q43054341-07431FD1-C2EC-4A7A-97B5-F6B71A4FCD14 Q44404129-41F0B5ED-EA77-409E-9294-7EDDBC88C883 Q44696507-C513AD61-F6DA-405E-9F88-7C5679E50A51 Q50944543-83528C93-E7AC-4C7A-88B5-13218EC0E8FD Q51060956-57339882-8D7B-42D2-B730-B1795EAADA93

P2860

Value based pricing for NHS drugs: an opportunity not to be missed?

http://www.wikidata.org/entity/Q36420631

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Value based pricing for NHS drugs: an opportunity not to be missed?

@ast

Value based pricing for NHS drugs: an opportunity not to be missed?

@en

type

label

Value based pricing for NHS drugs: an opportunity not to be missed?

@ast

Value based pricing for NHS drugs: an opportunity not to be missed?

@en

prefLabel

Value based pricing for NHS drugs: an opportunity not to be missed?

@ast

Value based pricing for NHS drugs: an opportunity not to be missed?

@en

P1433

Q36420631-F04DBF98-7F93-415D-ACCD-9CCB444A32ED

P1476

Q36420631-44801893-DEC5-4216-BDFE-86297AA3711C

P2093

Q36420631-1CEB5440-6E6D-4672-B8C2-61999DC438D4

Q36420631-2714F0A9-9536-412F-B716-6BC804578586

Q36420631-4479D247-308D-403A-8DAE-5C97BF3A7E15

Q36420631-5B7EA0A5-BE74-49CC-9741-5E9E20DD0B06

Q36420631-73C8520A-D435-47BA-A29A-6DC06D794F60

Q36420631-E1B15044-BDBA-46D6-BB0D-7639BF088D77

Q36420631-E7DB43A9-5796-4E42-A3A7-A08A8CB48DB8

P2860

Q36420631-132AB456-46F6-4C87-B1FF-90B3749877DF

Q36420631-3ECBD3A8-1EC1-4933-993D-F3C6C4EF2B16

Q36420631-56CC1761-ECB0-4EDB-8C93-3DF5C8CF8E31

Q36420631-8C6AD705-FC51-45A3-B5AF-5FD688BD3649

Q36420631-D0B67801-8AD0-400D-8813-BE55336DFE92

P304

Q36420631-46F71EFC-F091-4A69-8915-D1B9E3192E7A

P31

Q36420631-AE4AC6F4-3C16-4B24-A692-3859E71B65B9

P356

Q36420631-611787BF-9D89-4919-A0F4-0483C5842D5D

P407

Q36420631-ADAF2918-DED9-4A29-AED9-F500FEF73FA7

P433

Q36420631-6097977B-E0B2-4002-A93E-85BF80CF17A6

P478

Q36420631-5327DB34-CD1C-4988-BED2-CEAB79D47331

P577

Q36420631-99C5D91F-2BF3-4A1A-B2CC-AE645D6F4833

P5875

Q36420631-36FC6ACC-BF23-41D7-B1AD-79297786B36B

P698

Q36420631-3060F69D-7E7B-4DC9-AB8C-ED57344E0517

P932

Q36420631-1416F014-29CE-4D73-9DC1-3CCBF74CE968

P356

BMJ.39434.500185.25

P1433

P1476

Value based pricing for NHS drugs: an opportunity not to be missed?

@en

P2093

Andrew Briggs

http://www.w3.org/2001/XMLSchema#string

Anthony J Culyer

http://www.w3.org/2001/XMLSchema#string

Christopher McCabe

http://www.w3.org/2001/XMLSchema#string

Karl Claxton

http://www.w3.org/2001/XMLSchema#string

Mark J Sculpher

http://www.w3.org/2001/XMLSchema#string

Martin J Buxton

http://www.w3.org/2001/XMLSchema#string

Simon Walker

http://www.w3.org/2001/XMLSchema#string

P2860

Using value of information analysis to prioritise health research: some lessons from recent UK experience.

Dangerous omissions: the consequences of ignoring decision uncertainty.

Parliamentary review asks NICE to do better still.

The pharmaceutical price regulation scheme.

P304

251-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.39434.500185.25

http://www.w3.org/2001/XMLSchema#string

P407

P433

7638

http://www.w3.org/2001/XMLSchema#string

P478

336

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5607211

http://www.w3.org/2001/XMLSchema#string

P698

18244997

http://www.w3.org/2001/XMLSchema#string

P932

2223028

http://www.w3.org/2001/XMLSchema#string